Biosimulation Market By Product, By Application, By Delivery model, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "Biosimulation Market," The biosimulation market was valued at $2.5 billion in 2022, and is estimated to reach $10.6 billion by 2032, growing at a CAGR of 15.8% from 2023 to 2032. The computer-assisted simulation of biological processes that are essential to human biology is known as biosimulation. The goal of biosimulation is to offer model-based predictions of the dynamics and behavior of a biological system. A simulation model translates the knowledge about the biological system into mathematical equations. In the initial stage of the drug development process, one is anticipated to use the simulation model to test any hypothesis and change the product in order to optimize its function or estimate the chances that a given agent is projected to function as a drug, even before the first molecule is produced. The simulation model is anticipated to be used as a vehicle to define an effective test protocol and to check that information obtained from tests is consistent.

Pre-clinical testing of novel medicines, lead identification and optimization, target identification and validation are some primary areas where biosimulation is being used in drug R&D. Biosimulation forms the backbone of "virtual" drug trials, whose aim is to accurately predict the way medicines and diseases behave in the body by applying principles from biology, chemistry, and pharmacology with proprietary algorithms. In addition, this work includes gathering critical insights concerning drug interactions, safe dosing, toxicity predictions, and more.

Major factors that drive the growth of the global biosimulation market include an increase in demand for drug discovery and development, rise in need for personalized medicines, and surge in technological advancement in biosimulation software and devices. For instance, in June 2022, Certara, a global leader in biosimulation, released the new versions of immunogenicity (IG), immuno-oncology (IO) and vaccine simulators to help predict how drugs work and address key questions in the development of novel biologic therapies.

Furthermore, increase in R&D investment in pharmaceutical & biotechnology industries for the development of novel drug therapies and increase in prevalence of chronic diseases such as cancer, diabetes, Alzheimer's, cardiovascular disease, kidney disorders, and various others are the major factors that increase the demand for biosimulation software and hence propel the growth of the market. In addition, rise in demand to reduce drug discovery and development costs and increase in penetration of biosimulation software in contract research organization (CROs) and academic research institutes for drug discovery and development are the major factors that boost the growth of the biosimulation market.

However, the lack of standardized formats, protocols, and interoperability between different simulation platforms and limited awareness and education about biosimulation techniques among researchers and healthcare professionals restrain the growth of the biosimulation market. On the contrary, the expanding applications and increased use of personalized medicine and biosimulation solutions for pediatric drug development are expected to provide additional opportunities for the biosimulation market to grow in the coming years.

The global biosimulation market is segmented into product, application, end user, and region. On the basis of product, the market is bifurcated into software and services. On the basis of delivery model, the market is segmented into subscription model and ownership model. On the basis of application, it is segregated into drug development, drug discovery and others. On the basis of end user, it is segmented into pharmaceutical and biotechnology companies, contract research organization (CROs) and academic and research institutes. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are Dassault Systemes, VeriSIM Life, Certara Inc, Genedata AG, SimBioSys, Physiomics PLC, INOSIM Software GmbH, Schrodinger, Inc. Simulation Plus Inc, and Cadence Design Systems, Inc. The key players such as Simulation Plus Inc, Cadence Design Systems Inc, VeriSIM Life, Certara Inc, Schrodinger Inc, and Genedata AG have adopted product launch, acquisition, collaboration, partnership, and business expansion as major developmental strategies to improve the product portfolio of the biosimulation market.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biosimulation market analysis from 2022 to 2032 to identify the prevailing biosimulation market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the biosimulation market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global biosimulation market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

Market share analysis of players by products/segments
New Product Development/ Product Matrix of Key Players
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Average Selling Price Analysis / Price Point Analysis
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Product

Software
Services

By Application

Drug Development
Drug Discovery
Others

By Delivery model

Subscription Model
Ownership Model

By End User

Pharmaceutical and Biotechnology Companies
Contract Research Organization (CROs)
Academic and Research Institutes

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Latin America
- Middle East
- Africa

Key Market Players:

SimBioSys
Physiomics Plc
Genedata AG
Simulations Plus, Inc.
Cadence Design Systems, Inc.
Certara, Inc.
VeriSIM Life
Schrodinger, Inc.
Dassault Systemes
INOSIM Software GmbH

Product Code: A00288

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Growth in adoption of biosimulation software
  - 3.4.1.2. Technological advancements in biosimulation software
  - 3.4.1.3. Increase in demand to curtail drug discovery and development costs

3.4.2. Restraints
- 3.4.2.1. Lack of standardization and interoperability

3.4.3. Opportunities
- 3.4.3.1. Expansion of applications of biosimulation and increase in demand for personalized medicine.

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: BIOSIMULATION MARKET, BY PRODUCT

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Software
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Services
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: BIOSIMULATION MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Drug Development
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Drug Discovery
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: BIOSIMULATION MARKET, BY DELIVERY MODEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Subscription Model
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Ownership Model
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country

CHAPTER 7: BIOSIMULATION MARKET, BY END USER

7.1. Overview
- 7.1.1. Market size and forecast
7.2. Pharmaceutical and Biotechnology Companies
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
7.3. Contract Research Organization (CROs)
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
7.4. Academic and Research Institutes
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country

CHAPTER 8: BIOSIMULATION MARKET, BY REGION

8.1. Overview
- 8.1.1. Market size and forecast By Region
8.2. North America
- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by Product
- 8.2.3. Market size and forecast, by Application
- 8.2.4. Market size and forecast, by Delivery model
- 8.2.5. Market size and forecast, by End User
- 8.2.6. Market size and forecast, by country
  - 8.2.6.1. U.S.
  - 8.2.6.1.1. Market size and forecast, by Product
  - 8.2.6.1.2. Market size and forecast, by Application
  - 8.2.6.1.3. Market size and forecast, by Delivery model
  - 8.2.6.1.4. Market size and forecast, by End User
  - 8.2.6.2. Canada
  - 8.2.6.2.1. Market size and forecast, by Product
  - 8.2.6.2.2. Market size and forecast, by Application
  - 8.2.6.2.3. Market size and forecast, by Delivery model
  - 8.2.6.2.4. Market size and forecast, by End User
  - 8.2.6.3. Mexico
  - 8.2.6.3.1. Market size and forecast, by Product
  - 8.2.6.3.2. Market size and forecast, by Application
  - 8.2.6.3.3. Market size and forecast, by Delivery model
  - 8.2.6.3.4. Market size and forecast, by End User
8.3. Europe
- 8.3.1. Key market trends, growth factors and opportunities
- 8.3.2. Market size and forecast, by Product
- 8.3.3. Market size and forecast, by Application
- 8.3.4. Market size and forecast, by Delivery model
- 8.3.5. Market size and forecast, by End User
- 8.3.6. Market size and forecast, by country
  - 8.3.6.1. Germany
  - 8.3.6.1.1. Market size and forecast, by Product
  - 8.3.6.1.2. Market size and forecast, by Application
  - 8.3.6.1.3. Market size and forecast, by Delivery model
  - 8.3.6.1.4. Market size and forecast, by End User
  - 8.3.6.2. France
  - 8.3.6.2.1. Market size and forecast, by Product
  - 8.3.6.2.2. Market size and forecast, by Application
  - 8.3.6.2.3. Market size and forecast, by Delivery model
  - 8.3.6.2.4. Market size and forecast, by End User
  - 8.3.6.3. UK
  - 8.3.6.3.1. Market size and forecast, by Product
  - 8.3.6.3.2. Market size and forecast, by Application
  - 8.3.6.3.3. Market size and forecast, by Delivery model
  - 8.3.6.3.4. Market size and forecast, by End User
  - 8.3.6.4. Italy
  - 8.3.6.4.1. Market size and forecast, by Product
  - 8.3.6.4.2. Market size and forecast, by Application
  - 8.3.6.4.3. Market size and forecast, by Delivery model
  - 8.3.6.4.4. Market size and forecast, by End User
  - 8.3.6.5. Spain
  - 8.3.6.5.1. Market size and forecast, by Product
  - 8.3.6.5.2. Market size and forecast, by Application
  - 8.3.6.5.3. Market size and forecast, by Delivery model
  - 8.3.6.5.4. Market size and forecast, by End User
  - 8.3.6.6. Rest of Europe
  - 8.3.6.6.1. Market size and forecast, by Product
  - 8.3.6.6.2. Market size and forecast, by Application
  - 8.3.6.6.3. Market size and forecast, by Delivery model
  - 8.3.6.6.4. Market size and forecast, by End User
8.4. Asia-Pacific
- 8.4.1. Key market trends, growth factors and opportunities
- 8.4.2. Market size and forecast, by Product
- 8.4.3. Market size and forecast, by Application
- 8.4.4. Market size and forecast, by Delivery model
- 8.4.5. Market size and forecast, by End User
- 8.4.6. Market size and forecast, by country
  - 8.4.6.1. Japan
  - 8.4.6.1.1. Market size and forecast, by Product
  - 8.4.6.1.2. Market size and forecast, by Application
  - 8.4.6.1.3. Market size and forecast, by Delivery model
  - 8.4.6.1.4. Market size and forecast, by End User
  - 8.4.6.2. China
  - 8.4.6.2.1. Market size and forecast, by Product
  - 8.4.6.2.2. Market size and forecast, by Application
  - 8.4.6.2.3. Market size and forecast, by Delivery model
  - 8.4.6.2.4. Market size and forecast, by End User
  - 8.4.6.3. Australia
  - 8.4.6.3.1. Market size and forecast, by Product
  - 8.4.6.3.2. Market size and forecast, by Application
  - 8.4.6.3.3. Market size and forecast, by Delivery model
  - 8.4.6.3.4. Market size and forecast, by End User
  - 8.4.6.4. India
  - 8.4.6.4.1. Market size and forecast, by Product
  - 8.4.6.4.2. Market size and forecast, by Application
  - 8.4.6.4.3. Market size and forecast, by Delivery model
  - 8.4.6.4.4. Market size and forecast, by End User
  - 8.4.6.5. South Korea
  - 8.4.6.5.1. Market size and forecast, by Product
  - 8.4.6.5.2. Market size and forecast, by Application
  - 8.4.6.5.3. Market size and forecast, by Delivery model
  - 8.4.6.5.4. Market size and forecast, by End User
  - 8.4.6.6. Rest of Asia-Pacific
  - 8.4.6.6.1. Market size and forecast, by Product
  - 8.4.6.6.2. Market size and forecast, by Application
  - 8.4.6.6.3. Market size and forecast, by Delivery model
  - 8.4.6.6.4. Market size and forecast, by End User
8.5. LAMEA
- 8.5.1. Key market trends, growth factors and opportunities
- 8.5.2. Market size and forecast, by Product
- 8.5.3. Market size and forecast, by Application
- 8.5.4. Market size and forecast, by Delivery model
- 8.5.5. Market size and forecast, by End User
- 8.5.6. Market size and forecast, by country
  - 8.5.6.1. Latin America
  - 8.5.6.1.1. Market size and forecast, by Product
  - 8.5.6.1.2. Market size and forecast, by Application
  - 8.5.6.1.3. Market size and forecast, by Delivery model
  - 8.5.6.1.4. Market size and forecast, by End User
  - 8.5.6.2. Middle East
  - 8.5.6.2.1. Market size and forecast, by Product
  - 8.5.6.2.2. Market size and forecast, by Application
  - 8.5.6.2.3. Market size and forecast, by Delivery model
  - 8.5.6.2.4. Market size and forecast, by End User
  - 8.5.6.3. Africa
  - 8.5.6.3.1. Market size and forecast, by Product
  - 8.5.6.3.2. Market size and forecast, by Application
  - 8.5.6.3.3. Market size and forecast, by Delivery model
  - 8.5.6.3.4. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

10.1. Certara, Inc.
- 10.1.1. Company overview
- 10.1.2. Key Executives
- 10.1.3. Company snapshot
- 10.1.4. Operating business segments
- 10.1.5. Product portfolio
- 10.1.6. Business performance
- 10.1.0. Key strategic moves and developments
10.2. Dassault Systemes
- 10.2.1. Company overview
- 10.2.2. Key Executives
- 10.2.3. Company snapshot
- 10.2.4. Operating business segments
- 10.2.5. Product portfolio
- 10.2.6. Business performance
10.3. Simulations Plus, Inc.
- 10.3.1. Company overview
- 10.3.2. Key Executives
- 10.3.3. Company snapshot
- 10.3.4. Operating business segments
- 10.3.5. Product portfolio
- 10.3.6. Business performance
- 10.3.0. Key strategic moves and developments
10.4. Genedata AG
- 10.4.1. Company overview
- 10.4.2. Key Executives
- 10.4.3. Company snapshot
- 10.4.4. Operating business segments
- 10.4.5. Product portfolio
- 10.4.0. Key strategic moves and developments
10.5. SimBioSys
- 10.5.1. Company overview
- 10.5.2. Key Executives
- 10.5.3. Company snapshot
- 10.5.4. Operating business segments
- 10.5.5. Product portfolio
10.6. Physiomics Plc
- 10.6.1. Company overview
- 10.6.2. Key Executives
- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio
- 10.6.6. Business performance
10.7. INOSIM Software GmbH
- 10.7.1. Company overview
- 10.7.2. Key Executives
- 10.7.3. Company snapshot
- 10.7.4. Operating business segments
- 10.7.5. Product portfolio
10.8. VeriSIM Life
- 10.8.1. Company overview
- 10.8.2. Key Executives
- 10.8.3. Company snapshot
- 10.8.4. Operating business segments
- 10.8.5. Product portfolio
- 10.8.0. Key strategic moves and developments
10.9. Schrodinger, Inc.
- 10.9.1. Company overview
- 10.9.2. Key Executives
- 10.9.3. Company snapshot
- 10.9.4. Operating business segments
- 10.9.5. Product portfolio
- 10.9.6. Business performance
- 10.9.0. Key strategic moves and developments
10.10. Cadence Design Systems, Inc.
- 10.10.1. Company overview
- 10.10.2. Key Executives
- 10.10.3. Company snapshot
- 10.10.4. Operating business segments
- 10.10.5. Product portfolio
- 10.10.6. Business performance
- 10.10.0. Key strategic moves and developments